Posted by Michael Wonder on 27 Apr 2025
Dupilumab for the treatment of patients with moderate to severe chronic obstructive pulmonary disease
24 April 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use of dupilumab in the NHS in England.
For the time being, dupilumab should not be used as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils, who are using:
- An inhaled corticosteroid, a long-acting adrenergic beta2 receptor agonist and a long-acting muscarinic receptor antagonist (triple therapy)
- A long-acting adrenergic beta2 receptor agonist and a long-acting muscarinic receptor antagonist (double therapy) if the use of an inhaled corticosteroid in not appropriate
